VIR Insider Trading

Insider Ownership Percentage: 15.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,216,070.22

Vir Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at Vir Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$326ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Vir Biotechnology Share Price & Price History

Current Price: $6.70
Price Change: Price Increase of +0.03 (0.45%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for VIR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$6.70Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Vir Biotechnology (NASDAQ:VIR)

65.32% of Vir Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VIR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$58Mbought$37MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M-$100M$0$100M$200MTotal InflowsTotal Outflows
Vir Biotechnology logo
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Read More on Vir Biotechnology

Today's Range

Now: $6.70
Low: $6.52
High: $6.71

50 Day Range

MA: $8.80
Low: $6.59
High: $11.20

52 Week Range

Now: $6.70
Low: $6.40
High: $14.45

Volume

717,714 shs

Average Volume

1,310,219 shs

Market Capitalization

$918.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Who are the company insiders with the largest holdings of Vir Biotechnology?

Vir Biotechnology's top insider investors include:
  1. Endurance (Cayman) Ltd Svf (Major Shareholder)
  2. Vicki L Sato (Director)
  3. George A Scangos (Director)
  4. Backer Marianne De (CEO)
  5. Phillip Pang (EVP)
  6. Phillip Pang (Insider)
  7. Ann M Hanly (EVP)
  8. Ann M Hanly (CTO)
  9. Steven J Rice (Insider)
  10. Sung Lee (CFO)
  11. Verneuil Vanina De (EVP)
  12. Brent Sabatini (CAO)
  13. Saira Ramasastry (Director)
  14. Janet Napolitano (Director)
Learn More about top insider investors at Vir Biotechnology.

Who are the major institutional investors of Vir Biotechnology?

Vir Biotechnology's top institutional investors include:
  1. Vanguard Group Inc. — 9.53%
  2. Orbimed Advisors LLC — 2.34%
  3. Geode Capital Management LLC — 1.59%
  4. Dimensional Fund Advisors LP — 1.39%
  5. Millennium Management LLC — 1.25%
  6. Charles Schwab Investment Management Inc. — 0.91%
Learn More about top institutional investors of Vir Biotechnology stock.

Which institutional investors are selling Vir Biotechnology stock?

In the previous quarter, VIR stock was sold by these institutional investors:
  1. Jefferies Financial Group Inc.
  2. Jefferies Financial Group Inc.
  3. D. E. Shaw & Co. Inc.
  4. Orbimed Advisors LLC
  5. Barclays PLC
  6. Nordea Investment Management AB
  7. ADAR1 Capital Management LLC
  8. Voloridge Investment Management LLC
In the last year, company insiders that have sold Vir Biotechnology company stock include:
  1. Endurance (Cayman) Ltd Svf (Major Shareholder)
  2. Vicki L Sato (Director)
  3. George A Scangos (Director)
  4. Backer Marianne De (CEO)
  5. Phillip Pang (EVP)
  6. Phillip Pang (Insider)
  7. Ann M Hanly (EVP)
  8. Ann M Hanly (CTO)
Learn More investors selling Vir Biotechnology stock.

Which institutional investors are buying Vir Biotechnology stock?

During the previous quarter, VIR stock was bought by institutional investors including:
  1. Baker BROS. Advisors LP
  2. Artisan Partners Limited Partnership
  3. Point72 Asset Management L.P.
  4. Dimensional Fund Advisors LP
  5. Millennium Management LLC
  6. Alta Partners Management Company L.P.
  7. Sphera Funds Management LTD.
  8. Walleye Capital LLC